A Phase 1, Single- and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MEDI4166 in Subjects with Type 2 Diabetes

Trial Identifier: D6240C00001
Sponsor: MedImmune, LLC
NCTID:: NCT02524782
Start Date: October 2015
Primary Completion Date: April 2017
Study Completion Date: April 2017
Condition: Diabetes: Type 2

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English translation
Spanish translation

Trial Locations

Country Location
United States of America, AL Anniston, AL, United States of America, 36207
United States of America, CA Chula Vista, CA, United States of America, 91911
United States of America, FL Jacksonville, FL, United States of America, 32216
United States of America, FL Miami, FL, United States of America, 33014
United States of America, FL South Miami, FL, United States of America, 33143
United States of America, NC Durham, NC, United States of America, 27710
United States of America, NC Raleigh, NC, United States of America, 27612
United States of America, OH Cincinnati, OH, United States of America, 45227
United States of America, TN Knoxville, TN, United States of America, 37920
United States of America, TX San Antonio, TX, United States of America, 78209
United States of America, TX San Antonio, TX, United States of America, 78229